Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. 1988

M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
Department of Medicine, University of Maryland School of Medicine, Baltimore.

The genes encoding the A (toxic) subunit of cholera toxin were deleted from pathogenic Vibrio cholerae O1 strain 569B by recombinant techniques, leaving intact production of immunogenic, non-toxic B subunit. The resultant strain, CVD 103, evaluated for safety, immunogenicity, and efficacy as a live oral vaccine, was highly attenuated and elicited strong antibacterial and antitoxic immune responses; a single dose significantly protected volunteers against challenge with pathogenic V cholerae O1 of either serotype or biotype. A further derivative, CVD 103-HgR, which has an Hg++-resistance gene to differentiate it from wild-type vibrios, was also well-tolerated, immunogenic, and protective; moreover, faecal excretion of this derivative was significantly lower than that of CVD 103, which should minimise environmental spread of the vaccine. CVD 103-HgR is a candidate for expanded clinical trials in endemic areas.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D002771 Cholera An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated. Vibrio cholerae Infection,Choleras,Infection, Vibrio cholerae,Infections, Vibrio cholerae,Vibrio cholerae Infections
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations

Related Publications

M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
January 2020, The American journal of tropical medicine and hygiene,
M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
January 2022, Expert review of vaccines,
M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
November 1989, Infection and immunity,
M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
September 1992, Lancet (London, England),
M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
February 2018, Vaccine,
M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
March 2021, The American journal of tropical medicine and hygiene,
M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
June 1992, The Journal of infectious diseases,
M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
July 1999, The Pediatric infectious disease journal,
M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
December 2020, The American journal of tropical medicine and hygiene,
M M Levine, and J B Kaper, and D Herrington, and J Ketley, and G Losonsky, and C O Tacket, and B Tall, and S Cryz
January 2016, Travel medicine and infectious disease,
Copied contents to your clipboard!